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  Background  The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy 
with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled 
epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 weeks) as adjuvant treatment in high-risk 
breast cancer patients. The objective of this study was to evaluate the safety and efficacy of epoetin alfa in a   
second randomization of the intense dose-dense arm.
  Methods  One thousand two hundred eighty-four patients were enrolled; 658 patients were randomly assigned to the IDD-ETC 
treatment group. Within the IDD-ETC group, 324 patients were further randomly assigned to the epoetin alfa group, and 
319 were randomly assigned to the non–erythropoiesis-stimulating agent (ESA) control group. Primary efficacy end-
points included change in hemoglobin level from baseline to Cycle 9 and the percentage of subjects requiring red blood 
cell transfusion. Relapse-free survival, overall survival, and intramammary relapse were secondary endpoints estimated 
with Kaplan-Meier and Cox regression methods. Except for the primary hypothesis, all statistical tests were two-sided.
  Results  Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs –2.20 g/dL change 
for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red 
blood cell transfusion (12.8% vs 28.1%; P < .0001). The incidence of thrombotic events was 7% in the epoetin alfa 
arm vs 3% in the control arm. After a median follow-up of 62 months, epoetin alfa treatment did not affect overall 
survival, relapse-free survival, or intramammary relapse.
  Conclusions  Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-
free or overall survival. However, epoetin alfa had an adverse effect, resulting in increased thrombosis.
    J Natl Cancer Inst;2013;105:1018–1026 
Anemia is frequent in cancer patients, especially in those receiving 
chemotherapy or radiotherapy and has a negative impact on the 
patient´s quality of life.
Established adjuvant chemotherapeutic regimens of breast can-
cer patients lead to a clinically significant degree of anemia. Even 
a standard anthracycline-containing regimen such as the French 
FEC regimen (5-fluorouracil, epirubicin, cyclophosphamide) 
induces anemia grades 1 to 3 in 42.4% of patients (1). Dose-dense 
combination regimens with granulocyte colony-stimulating fac-
tor (G-CSF) support (2) require red blood cell (RBC) transfusions 
in 13% of the patients and intense dose-dense regimens such as 
intense dose-dense (IDD) sequential chemotherapy with epiru-
bicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) or 
doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) (IDD-
ATC) require RBC transfusions in 25% to 67% of patients (3,4).
The erythropoiesis-stimulating agent (ESA) epoetin alfa 
had shown efficacy in treatment (5–9) and prevention (10,11) of 
chemotherapy-induced anemia in breast cancer patients. However, 
individual studies (12) and meta-analyses reported an increased risk 
of death and serious adverse events. Whereas three meta-analyses 
have indicated an increased risk of mortality with the use of ESAs 
(13–15), two other meta-analyses did not indicate that ESA use 
statistically significantly affected disease progression or mortality 
(16,17). In addition, there is strong evidence from meta-analyses 
of randomized trials that therapy with epoetin and darbepoetin 
increases the risk of thromboembolic events (13,15–17).
As a consequence, the revised US Food and Drug Administration 
label states that ESAs should only be used to treat chemotherapy-
induced anemia (18) and they should not be used in malignancies 
such as early-stage breast cancer when the anticipated treatment 
outcome is cure.
In contrast with these recommendations, which were not defined 
at the start of our trial, we evaluated epoetin alfa for prevention 
of chemotherapy-induced anemia in a curative indication. In a 
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preceding phase I/II dose-escalation study with 102 patients, 26% of 
these patients required RBC transfusions (3). This high percentage 
of RBC transfusion is not acceptable in the adjuvant setting and was 
the rationale for performing a second randomization of epoetin alfa 
vs control in the intense dose-dense ETC arm only. Comparing the 
effectiveness of IDD-ETC and conventionally scheduled epirubicin/
cyclophosphamide followed by paclitaxel, the 5-year event free 
survival rates (70% vs 62%) and overall survival rates (82% vs 77%) 
were statistically significantly improved by IDD-ETC (19).
We report data from the second randomization of epoetin alfa 
vs control in the IDD-ETC arm. Results of our study will contrib-
ute to the still ongoing discussion about the benefit and safety of 
ESAs in the treatment of cancer patients.
Methods
Objectives
The primary objectives were to determine the effect of epoetin 
alfa treatment compared with non-ESA control for patients in the 
IDD-ETC group with regard to hemoglobin (Hb) levels during 
chemotherapy and RBC transfusion requirements.
Secondary objectives were to determine the effect of epoetin 
alfa treatment with regard to the following: overall and recurrence-
free survival after 5 years, intramammary relapse, and assessment of 
health-related patient-reported outcomes and safety (thrombotic 
vascular events, serious adverse events, clinical laboratory tests).
The ethics committee of the University of Ulm provided 
approval for the study. At each participating institution, the study 
was additionally approved by the local institutional review board. 
All eligible patients provided written informed consent.
Patients
Women with histologically confirmed primary breast cancer of 
stages II to IIIa with four or more tumor-infiltrated axillary lymph 
nodes were eligible (20). Main inclusion criteria were age between 
18 and 65 years, M0 status, and R0 resection of the primary tumor 
and axilla with a minimum of 10 axillary lymph nodes removed. 
Additional eligibility criteria have been previously described in 
detail (19).
Treatment
IDD chemotherapy consisted of sequential administration of each 
of three cycles of epirubicin (E) (150  mg/m2 intravenously as a 
bolus infusion), paclitaxel (T) (225 mg/m2 intravenously as a 3-hour 
infusion), and cyclophosphamide (C) (2500 mg/m2 intravenously as 
a 2-hour infusion), respectively, every 2 weeks (IDD-ETC; arm 
A). All patients received filgrastim subcutaneously (5 µg/kg body 
weight per day) from days 3 to 10 of each cycle. The standard treat-
ment (arm B) consisted of 4 cycles of epirubicin/cyclophosphamide 
(90/600 mg/m2) followed by 4 cycles of paclitaxel (175 mg/m2) as a 
3-hour infusion (EC→T). All cycles were administered in 3-week 
intervals without growth factor support (Figure 1).
Complete blood counts were obtained at each cycle, and Hb 
level was measured at least weekly during chemotherapy.
Regular follow-up visits had to be performed every 3 months for 
the first 3 years, every 6 months during years 4 and 5, and annually 
thereafter.
Epoetin Alfa Regimen
Patients in the IDD-ETC arm were randomly assigned to receive 
epoetin alfa subcutaneously (150 IU/kg three times weekly) or no 
ESA treatment. ESA treatment started on day 1 and continued for 
up to 14 days after the last dose of cyclophosphamide. All patients 
also received 200 mg/day oral iron.
The objective of epoetin alfa treatment was to maintain an 
appropriate Hb level of 12.5 to 13.0  g/dL. Epoetin alfa had to be 
withdrawn when the Hb level exceeded 14.0  g/dL and could be 
restarted when the Hb level dropped to less than 13.0 g/dL. If the 
Hb level dropped by more than 2.0  g/dL within a 4-week period, 
the dose of epoetin alfa was to be doubled.
Patients with an Hb level below 9.0  g/dL were evaluated for 
the need of RBC transfusion. The indication for RBC transfusion 
depended on the symptoms of the patients and was at the discretion 
of the physician.
Epirubicin            Paclitaxel         Cyclophosphamide
150 mg/m²             225 mg/m²2 500 mg/m²
q2w3
G-CSF (Filgrastim)  Epoetin
×
q3w4 × q3w4 ×
q2w3 × q2w3 ×
-
+ TAM
+ TAM
EC 90/600 mg/m²
Paclitaxel 175 mg/m² 
R
( )
± α
Figure  1.  Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (IDD-ETC) vs conventionally dosed EC   
(epirubicin and cyclophosphamide) followed by paclitaxel (T) in patients with four or more lymph nodes. G-CSF = granulocyte colony-stimulating 
factor; q2w = every 2 weeks; q3w = every 3 weeks; TAM = Tamoxifen.Vol. 105, Issue 14  |  July 17, 2013 1020 Articles | JNCI
Statistical Analysis
Patients were stratified by center, menopausal status (pre- vs post-
menopausal), and the number of affected lymph nodes (4–9 vs 
≥10) at the central fax randomization. Computer-generated lists 
with permuted blocks of randomly variable size were used. Group 
assignment in all analyses was based on the randomization result.
The sample size of the Arbeitsgemeinschaft Gynäkologische 
Onkologie (AGO) trial was mainly driven by the requirements of the 
main research question on chemotherapy density and its long-term 
survival-type endpoint. Prospective power calculations revealed 
that the resulting sample size was sufficient to detect any meaning-
ful difference in Hb levels and proportions needing transfusion. In 
addition, the planned patient number attained approximately 85% 
power to detect a 10% difference in the 5-year relapse-free survival 
rate after a median follow-up of 5 years using a log-rank test.
The numbers of patients who received at least one on-study 
RBC transfusion were compared between the two groups using 
Fisher exact test. On-study was defined as the period from rand-
omization to the date of the last cycle of chemotherapy plus 14 days 
or the date of withdrawal, whichever occurred first.
Hb values at baseline, change from baseline to each post 
baseline time point, and change from baseline to the last on-
study assessment were to be presented. Comparison of Hb levels 
between the two groups was evaluated with analysis of variance and 
Wilcoxon tests.
Kaplan-Meier estimates of the relapse-free survival rate through 
the clinical cutoff date were presented by treatment group for the 
intent-to-treat population. Comparison of relapse-free survival 
between the 2 treatment groups was performed using a 2-sided log-
rank test with and without the stratification factors for menopausal 
status and number of positive lymph nodes. The reported P values 
result from the unstratified analyses. The results from the stratified 
analyses are virtually identical and therefore not represented.
In addition, Cox regression models, with and without adjustment 
for the stratification factors, were performed to calculate the 
hazard ratios (HRs) and associated 95% confidence intervals (CI). 
All statistical tests were two-sided, except for the primary endpoint 
of transfusions for which a one-sided hypothesis was prospectively 
defined based on previous knowledge of expected differences.
The impact of cancer and its treatment was assessed using the 
European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire, version 3. Patients had to complete 
the questionnaire before the start of treatment, at every second 
cycle, at the end of treatment, and at each follow-up visit.
results
One thousand two hundred eighty-four patients were recruited 
between November 1998 and April 2003 from 165 centers in 
Germany. Six hundred twenty-six subjects were randomly assigned   
to the EC→T regimen and 658 subjects were randomly assigned to 
the IDD-ETC treatment regimen. Of these, 643 subjects were further 
randomly assigned between the epoetin alfa group (n = 324) and the 
control group (n = 319) (CONSORT diagram, Figure 2). Median fol-
low-up duration was 62 months, but the study is ongoing for continued 
10-year follow-up.
The safety population included 627 subjects, 309 subjects in the 
epoetin alfa group and 318 subjects in the control group. The 16 
subjects excluded from the safety population were either assigned 
to the control group but received ESA treatment (n = 1 subject) or 
were assigned to the epoetin alfa group but did not receive epoetin 
alfa (n = 15 subjects). The per-protocol population included 511 
subjects, 258 subjects in the epoetin alfa group and 253 in the con-
trol group. All of these subjects received nine cycles of chemother-
apy. Excluded from the per-protocol population were subjects with 
unknown baseline Eastern Cooperative Oncology Group/World 
Health Organization performance status, subjects with less than 
four positive lymph nodes at baseline, and subjects who did not 
receive their assigned treatment. The majority of subjects excluded 
from the per-protocol population failed to complete nine cycles of 
chemotherapy.
Eighty-three percent of subjects completed the IDD-ETC arm 
(85% epoetin alfa group and 81% control group). “Serious adverse 
event” was cited as the reason for discontinuation for the majority 
of subjects from both the epoetin alfa group (n = 32 of 49 subjects) 
and the control group (n = 38 of 60 subjects). The two treatment 
groups were generally similar with respect to the demographic and 
baseline characteristics summarized in Table 1.
Epoetin Alfa Dosing
The median duration of epoetin alfa treatment was 18 weeks 
(mean = 16.9 weeks), and the median weekly dose received was 452 
IU/kg (mean = 441 IU/kg per week). Although epoetin alfa dosing 
information had to be reported in the case report form as the num-
ber of units administered per kilogram of body weight, a fixed dose 
of 10 000 IU was specified for some subjects. In these instances, a 
per-kilogram dose was calculated using the subject’s body weight.
Hb Levels
The median baseline Hb level was somewhat lower in the epoetin 
alfa group (12.40  g/dL; interquartile range [IQR] = 11.7–13.3g/
dL) than the control group (12.80  g/dL; IQR = 12.2–13.6  g/dL) 
and decreased for both groups over the first three cycles of chemo-
therapy. However, there was no decline from baseline to cycle 9 
in the epoetin alfa group (12.4  g/dL at both cycle 1 and cycle 9). 
In contrast, the decline from baseline to cycle 9 for patients in 
the control group was 2.20  g/dL (P < .001). Results of this analy-
sis for the intent-to-treat population were similar to those for the   
per-protocol population, and the results were confirmed when an 
analysis of variance model was employed.
Figure 3 reflects the myelosuppressive toxicities of IDD-ETC 
and the effect of epoetin alfa. Each point in Figure 3 represents the 
mean of the Hb values measured for a given cycle. The statistically 
significant difference between treatment groups is reflected in the 
final separation of Hb level curves.
Transfusion requirements
For the intent-to-treat population, more than twice as many 
subjects in the control group received at least one RBC transfusion 
during chemotherapy as compared with subjects in the epoetin 
alfa group (86 [28.1%] vs 41 [12.8%] subjects, respectively). The 
difference between groups was statistically significant (P < .0001). 
The estimated transfusion odds ratio for the overall treatment JNCI | Articles 1021 jnci.oxfordjournals.org
period was 0.37 (95% CI = 0.25 to 0.57). Similar results were 
obtained when the per-protocol population was analyzed.
Most transfusions, regardless of treatment group, occurred dur-
ing cycles 7 to 9. However, the number of subjects in the control 
group who received transfusions tended to increase steadily from 
cycle 1 onward to cycle 9, whereas the number of subjects in the 
epoetin alfa group who received transfusions increased mainly dur-
ing cycles 7 to 9.
Relapse-Free Survival
The Kaplan–Meier estimates of relapse-free survival for the intent-to-
treat population are shown in Figure 4. This analysis took into account 
any disease relapse or death as events. The 5-year relapse free survival 
rates were 71% (95% CI = 66% to 76%) and 72% (95% CI = 67% to 
77%) for subjects in the control and epoetin alfa groups, respectively. 
The hazard ratio was 1.03 (95% CI = 0.77 to 1.37), and the difference 
between groups was not statistically significant (P = .86).
Overall Survival
The Kaplan–Meier estimates of overall survival for the intent-to-
treat population are shown in Figure 5. The hazard ratio was 0.97 
(95% CI = 0.67 to 1.41), and the difference between groups was not 
statistically significant (P = .89).
The 5-year overall survival rates were 81% (95% CI = 76% to 
86%) and 83% (95% CI = 78% to 87%) for subjects in the epoetin 
alfa and control groups, respectively (P = .89).
Figure 2.  CONSORT trial flow diagram. EPO = epoetin alfa; ESA = erythropoiesis-stimulating agent; IDD-ETC = intense dose-dense sequential 
chemotherapy with epirubicin, paclitaxel, and cyclophosphamide.
Randomized to intensified vs
conventional adjuvant chemotherapy  
(n = 1284)
Conventional chemotherapy arm (no 
erythropoiesis-stimulating factor option) (n = 626)
Noneligible or early withdrawal of consent 
(n = 15)
Analyzed  (n = 309)
No data on red blood cell transfusion 
available( n = 10)
Allocated to non-EPO control( n = 319)
Analyzed  (n = 320)
No data on red blood cell transfusion
available( n = 4)
Allocated to epoetin alfa (n = 324)
Analysed  (n=  )
Allocation
Primary endpoint
IDD-ETC: Randomized to EPO vs control( n = 643)
Enrollment
Analyzed for relapse-free and overall survival 
(n = 324)
Analyzed for relapse-free and overall survival 
(n = 317)
No data available beyond baseline (n = 2)
Follow-up
Analyzed for safety parameters( n = 309)
Did not receive EPO treatment (n = 15)
Analyzed for safety parameters (n = 318)
Received EPO treatment (n = 1)
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Table 1.  Demographic and baseline characteristics (intent-to-treat population)*
Characteristic Non-EPO control, No. (%) EPO, No. (%)
No. 319 324
Age, years
Median 52 50
Range 28–67 29–65
Body mass index, kg/m2
Median 24.5 24.4
Range 17–42 17–48
Positive lymph nodes, No. (%)
4–9 185 (58) 191 (59)
≥10 134 (42) 133 (41)
Menopausal status, No. (%)
Premenopausal 143 (45) 163 (51)
Postmenopausal 176 (55) 160 (49)
Tumor stage, No. (%)
pT1 100 (31) 81 (25)
pT2 172 (54) 190 (59)
pT3 46 (14) 50 (15)
Baseline hemoglobin level, g/dL
No. 303 313
Median 12.8 g/dL 12.4 g/dL
Range 9.0–16.0 g/dL 9.0–16.0 g/L
HER2+
No. 319 322
Positive, No. (%) 83 (26) 79 (25)
Negative, No. (%) 183 (57) 189 (59)
Not performed, No. (%) 53 (17) 54 (17)
ECOG
No. 312 315
ECOG 0, No. (%) 260 (83) 254 (81)
ECOG 1, No. (%) 52 (17) 61 (19)
ER status
No. 317 322
Positive, No. (%) 221 (70) 244 (76)
Negative, No. (%) 96 (30) 78 (24)
*  ECOG = Eastern Cooperative Oncology Group; ER = estrogen receptor; EPO = epoetin alfa.
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Safety
The overall incidence of serious adverse events was 11% and was 
similar in both groups: 10% in the epoetin alfa group and 13% in 
the control group.
Thirty-nine (13%) of the 309 subjects in the epoetin alfa group 
and 22 (7%) of the 318 subjects in the non-ESA control group 
were reported to have experienced at least one thrombotic vascular 
event while on chemotherapy. The summary of clinically relevant 
IDD-ETC 5-year EFS rate = 71%
IDD-ETC + EPO 5-year EFS rate = 72%
01 02 03 04 05 06 07 08 09 0
0.0
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Log-rank test: P  = .86; two-sided HR = 1.03; 95% CI = 0.77 to 1.37
Months
Numbers 
at risk
ETC 317 271 215 125 12
ETC + EPO 324 295 238 108 13
Figure 4.  Kaplan–Meier curve of relapse-free survival (intent-to-treat population) Log-rank test. All statistical tests were two-sided. CI = confidence 
interval; EFS = event-free survival; EPO = epoetin alfa; ETC = epirubicin, paclitaxel, and cyclophosphamide; HR = hazard ratio.
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Months
Numbers 
at risk
ETC3 17 3022 46 142 12
ETC + 
EPO
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Log-rank test: P = .89; two-sided; HR = 0.97; 95% CI = 0.67 to 1.41
ETC: n = 317, 55 events
ETC + EPO: n = 324, 59 events
Figure 5.  Kaplan–Meier curve of overall survival (intent-to-treat population). Log-rank test. All statistical tests were two-sided. CI = confidence inter-
val; EPO = epoetin alfa; ETC = epirubicin, paclitaxel, and cyclophosphamide; HR = hazard ratio; OS = overall survival.Vol. 105, Issue 14  |  July 17, 2013 1024 Articles | JNCI
thrombotic vascular events is presented in Table 2. Fewer subjects 
in the control group experienced clinically relevant thrombotic vas-
cular events compared with subjects in the epoetin alfa group (10 
[3%] vs 22 [7%] subjects, respectively; P = .03, Fisher exact test).
Quality of Life
Results for health-related patient-reported outcome analyses are 
not presented because of the large amount of missing baseline data 
(in excess of 40% of baseline measurements were missing).
Discussion
The use of epoetin alfa in the IDD-ETC arm statistically significantly 
reduced the rate of RBC transfusion (12.8% vs 28.2% of subjects;   
P < .001) and avoided the chemotherapy-induced decline in Hb level 
as compared with patients in the non-ESA control group.
Regarding the discussions of the last decade, there are concerns 
that ESAs could increase mortality in cancer patients. The Breast 
Cancer Erythropoietin Survival Trial (BEST) (12) was one of 
the first randomized studies that reported an increased mortality 
in metastatic breast cancer patients receiving epoetin alfa. The 
first meta-analysis that identified increased mortality by ESA use 
(HR = 1.10; 95% CI = 1.01 to 1.20) was published by Bennett 
et al. (13). These authors identified eight studies that individually 
demonstrated increased mortality and/or tumor progression 
among patients treated with ESAs (12,21–27). However, it should 
be noted that only two of these trials treated breast cancer patients 
(metastatic and neoadjuvant); dominant tumor entities were head 
and neck, cervical, lympho-proliferative, and non–small cell lung 
carcinoma. Bohlius et al. (14) reported results from the independent 
patient data meta-analysis for on-study deaths and overall survival 
and concluded that ESA use increased mortality during the active 
study period (HR = 1.17; 95% CI = 1.06 to 1.30) and worsened 
overall survival (HR = 1.06; 95% CI = 1.00 to 1.12). However, in 
patients receiving chemotherapy, a statistically significant difference 
between the ESA and control groups (on-study death HR = 1.10, 
95% CI = 0.98 to 1.24; overall survival HR = 1.04, 95% CI = 0.97 
to 1.11) was not observed. An erratum regarding a correction of the 
upper limit of the x-axis should be noted (28). The meta-analysis 
of Tonelli et al. (15) also confirmed that all-cause mortality during 
treatment was statistically significantly higher in the group receiving 
erythropoiesis-stimulating therapy than in the control group.
In contrast, two meta-analyses (16,17) could not confirm these 
safety concerns. The Glaspy et  al. meta-analysis (16) included 
studies from the 2006 Cochrane meta-analysis, studies published/
updated since the 2006 Cochrane report, and unpublished trial 
data from Amgen and Johnson and Johnson. Their results indi-
cated that ESA use did not statistically significantly affect mortal-
ity (HR = 1.06; 95% CI = 0.97 to 1.15) or disease progression (26 
studies: HR = 1.01; 95% CI = 0.90 to 1.14).
Ludwig et al. (17) conducted a pooled analysis of individual 
patient-level data from all randomized, double-blind, placebo-con-
trolled trials in patients receiving darbepoetin alfa or placebo. They 
found no association between darbepoetin alfa and risk for death or 
disease progression. Taken together, the results and conclusions of 
these meta-analyses remain controversial.
In our analysis of the IDD-ETC arm, the Kaplan–Meier analy-
sis of relapse-free survival showed no difference between the epo-
etin alfa and the control group. The hazard ratio was 1.03 (95% 
CI = 0.77 to 1.37; P = .86). Further, for the overall survival analy-
sis, the Kaplan–Meier analysis showed no significant difference 
between the two arms (P = .89), neither indicating a benefit of 
maintaining Hb levels and reducing transfusion nor showing any 
hint for a detrimental effect of epoetin application during dose-
dense and dose-intensified chemotherapy.
Our results are in accordance with two large recently reported 
studies in the adjuvant treatment of lymph node–positive breast 
cancer patients receiving chemotherapy. In the previously reported 
ARAplus trial (29), patients receiving either the TAC (docetaxel, 
doxorubicin, cyclophosphamide) or the FEC (5-fluorouracil, epiru-
bicin, cyclophosphamide) regimen were randomly assigned between 
darbepoetin alfa or standard supportive care. The analysis of 1198 
evaluable patients showed no difference in the event-free and overall 
survival between the groups, and no excess on-study mortality was 
observed in the ESA arm when compared with control patients.
The NSABP B-38 trial compared TAC vs dose-dense AC→ 
paclitaxel (every 2 weeks) ± gemcitabine (30). ESAs were given in 
all three arms if Hb was below 11 g/dL. A statistically significantly 
higher incidence of grade 2 anemia was reported for the two dose-
dense arms in comparison with TAC. Two thousand one hundred 
forty-nine of 4894 included patients in this trial received ESAs. 
With a median follow-up duration of 5.3 years, exploratory analysis 
revealed no differences regarding disease-free (HR  =  1.02) or 
overall survival (HR = 1.04).
Table 2.  Clinically relevant thrombotic vascular events (safety population)*
Chosen MedDRA body system/organ 
class Chosen MedDRA preferred term
Non-EPO control  
(n = 318), No. (%)
EPO  
(n=309), No. (%)
Total (N = 627),   
No. (%)
Total No. of subjects with adverse events 10 (3) 22 (7) 32 (5)
Vascular disorders 10 (3) 22 (7) 32 (5)
 Thrombosis 9 (3) 21 (7) 30 (5)
  Venous thrombosis 0 2 (1) 2 (<1)
  Arterial thrombosis 0 1 (<1) 1 (<1)
  Deep vein thrombosis 0 1 (<1) 1 (<1)
 Embolism 1 (<1) 0 1 (<1)
  Subclavian vein thrombosis 1 (<1) 0 1 (<1)
Respiratory, thoracic, and mediastinal disorders 1 (<1) 0 1 (<1)
  Pulmonary embolism 1 (<1) 0 1 (<1)
*  Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events. Percentage calculated with the number of 
subjects in each group as the denominator. EPO = epoetin alfa; MedDRA = Medical Dictionary for Regulatory Activities.JNCI | Articles 1025 jnci.oxfordjournals.org
The fourth randomized trial in the curative setting of breast cancer 
patients was the neoadjuvant PREPARE trial (26,31). The PREPARE 
study compared a sequential IDD regimen of epirubicin and paclitaxel 
(every 2 weeks) followed by conventional cyclophosphamide, 5-fluo-
rouracil, and methotrexate vs conventionally scheduled epirubicin/
cyclophosphamide followed by paclitaxel. Again, in both arms, sub-
jects were randomly assigned to receive either darbepoetin alfa or no 
treatment to prevent anemia and potentially augment the therapeutic 
effects of chemotherapy. Three-year disease-free survival was 74.3% 
with darbepoetin vs 80% without (HR = 1.31; P = .06), and overall 
survival was 88% with darbepoetin vs 91.8% without (HR = 1.33; 
P = .14). Although not statistically significant, these results suggest a 
negative impact on disease progression.
Although all four trials were conducted with curative intent, 
they differ in important points. Only the PREPARE trial included 
patients in the neoadjuvant treatment setting. The ETC trial is the 
only trial that exclusively recruited patients undergoing an anemia-
causing regimen. WSG-ARA plus, PREPARE, and NSABP B-38 
included, at least in part, patients receiving non-anemia-causing 
regimens. Correspondingly, the mean Hb concentration for the 
epoetin alfa treatment group in the IDD-ETC arm was lower at 
the end of chemotherapy (12.4 g/dL) as compared with patients in 
the PREPARE study (13.6 g/dL).
In a review of the literature, preclinical data are ambiguous 
regarding a direct or indirect effect of ESAs on tumor growth (32). 
A study by Bennett et al. (33) reported that academic research-
ers without pharmaceutical manufacturer research/funding more 
often report both direct and indirect effects of ESAs on tumor 
growth, in contrast with researchers with pharmaceutical funding. 
The results of these studies support the hypothesis that the risk of 
potential tumor progression and decreased survival by the use of 
ESAs could be mainly restricted to the metastatic and neoadjuvant 
treatment situations (12,31) in which patients have relevant tumor 
load. In this clinical setting, ESAs may accentuate tumor growth by 
stimulation of erythropoietin receptors on tumor cells (despite the 
questions on antibody specificity in epoetin (EPO) receptor meas-
urement) (34,35). In contrast, trials in the adjuvant setting, such 
as AGO-ETC, ARA plus (29), and NSABP B-38 (30), showed no 
adverse effect of ESAs on disease-free and overall survival.
There is now strong and consistent evidence from individual 
trials and from meta-analyses that therapy with ESAs increases 
the risk of thromboembolic events. Bennett et al. (13) reported 
a 1.57-fold increased venous thromboembolism (VTE) risk with 
ESA administration, which was confirmed by the majority of ran-
domized phase III trials (36) and published overviews (13,15–17). 
Specific risk factors in addition to the general risk factors for throm-
botic events have not been defined in these trials. Our study also 
confirmed an elevated risk of venous thrombotic events in patients 
receiving epoetin alfa, but fortunately we observed no pulmonary 
embolism or fatal event. This increased risk of thromboembolism 
is consistent with the current epoetin alfa labeling.
The IDD-ETC regimen is highly effective and safe (19) but has 
a pronounced hematological toxicity. Our study did not evaluate 
treatment of chemotherapy-induced anemia as much as prevention 
of this anemia. With regard to the rapid decline of the Hb level in 
the non-ESA control group despite a more than twofold higher 
transfusion rate, primary prophylaxis of anemia is indicated. This 
is in contrast with guidelines in Canada and the United States and 
with the pharmaceutical manufacturers product label that indicate 
these agents should not be used when patients receive chemother-
apy with curative intent. Primary prevention is, at least, partially 
supported by the updated guidelines of the European Organization 
for Research and Treatment of Cancer,37 which considers ESA use 
in selected asymptomatic chemotherapy patients to prevent a fur-
ther decline in Hb level according to individual factors (eg, type/
Intensity and duration of chemotherapy) (37,38).
We have shown a beneficial effect of epoetin alfa in the adjuvant 
treatment of breast cancer patients receiving IDD chemotherapy 
without deleterious effects on disease progression or mortality after 
almost 5 years of follow-up. However, the size of our study was not 
large enough to detect any negative effects on survival between epo-
etin alfa and no epoetin alfa. In accordance with the literature, we 
confirmed the known detrimental effects on thrombotic complica-
tions. With the exception of this risk, ESAs appear to be safe drugs 
for the treatment of chemotherapy-induced anemia or the primary 
prevention of anemia in patients with IDD chemotherapy regimens. 
Regarding the effects of ESAs, our results were confirmed by a recent 
clinical trial whose formal primary endpoint was survival. Data from 
this study also suggest that ESAs have no detrimental effect on dis-
ease progression in breast cancer patients undergoing adjuvant chem-
otherapy (29).
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